CClinicalTrials.gg
Active, not recruitingNCT05557617Updated Apr 10, 2024

Periodontitis and Periodontal Bacteria in Dementia

An observational study in Alzheimer Disease, Dementia and Periodontitis, sponsored by Region Örebro County. Active, not recruiting at 1 site in Sweden. Open to participants aged 25 Years to 110 Years. Per ClinicalTrials.gov, last updated 2024-04-10.

Sponsored by Region Örebro County · Observational

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 9 months ago, but the record still lists the study as active, not recruiting.
Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
120
Ages
25 Years to 110 Years
Sex
All
01

Study summary

The study is designed to inquire whether the presence of periodontitis and different periodontopathogenic bacterial strains are associated with dementia diagnosis and with the degree of cognitive impairment in participants evaluated at a Memory clinic (Minnesmottagning). Specifically, by analyzing cerebrospinal fluid, the investigators intend to clarify whether the alleged mechanisms for Porphyromonas gingivalis in the aetiology of Alzheimer disease (AD) are supported in a Swedish population and whether they are specific for Porphyromonas gingivalis (as compared to other periodontopathogenic bacteria) and Alzheimer type dementia (as compared to other etiological dementia types), respectively.

Read the detailed description

Purpose and aims

The study is designed to inquire whether the presence of periodontitis and different periodontopathogenic bacterial strains are associated with dementia diagnosis and with the degree of cognitive impairment in patients evaluated at a Memory clinic (Minnesmottagning). Specifically, by analyzing cerebrospinal fluid (CSF) samples, the investigators intend to clarify whether the alleged mechanisms for Porphyromonas gingivalis (P. gingivalis) in the aetiology of AD are supported in a Swedish population and whether they are specific for P. gingivalis (as compared to other periodontopathogenic bacteria) and Alzheimer type dementia (as compared to other etiological dementia types), respectively.

Research questions

In what proportion of Swedish dementia cases is bacterial DNA from periodontal pathogens, antibodies against periodontal pathogens, gingipain protein from P. gingivalis and gingipain enzyme activity found in CSF? Are these bacteriological findings in the CSF more common or more elevated in individuals that received a diagnosis of dementia, as compared to individuals with a lower level of cognitive dysfunction (e.g. mild cognitive impairment, subjective cognitive impairment, or no diagnosis)? Are measurements of cognitive function, e.g. mini-mental state examination (MMSE) scores, correlated with bacteriological findings in the CSF, including gingipain activity? Is the prevalence of periodontitis higher in participants that received a diagnosis of dementia, as compared to participants with a lower level of cognitive dysfunction? Was the prevalence of periodontitis, 5 - 15 years prior to the diagnostic evaluation, higher in participants that received a diagnosis of dementia, as compared to participants with a lower level of cognitive dysfunction? Are measurements of cognitive function, e.g. mini-mental state examination (MMSE) scores, correlated with periodontitis-related findings? In that case, does the correlation depend on the time interval between the periodontal and the cognitive assessments? Are the above bacteriological findings in the CSF more common or more elevated in participants with severe periodontitis, as compared to participants with mild or no periodontitis? Are periodontitis-related findings correlated with bacteriological findings in the CSF, including gingipain activity? In that case, does the correlation depend on the time interval between the periodontal assessments and the CSF sample? Are P. gingivalis-related findings more common or more pronounced than findings related to other periodontal pathogens in any of these potential relationships? Are P. gingivalis-related findings and other bacteriological findings in the CSF more common or more elevated in participants with AD, as compared to participants with non-Alzheimer dementias? Are P. gingivalis-related findings and other bacteriological findings in the CSF correlated with AD-markers in the CSF, such as β-amyloid, tau and phospho-tau?

Participants

The study is based on a cohort of participants that has been investigated for assumed cognitive impairment at the Memory Clinic (Minnesmottagningen), Department of Geriatric Medicine, Örebro University Hospital. The clinical examination includes cognitive tests, brain imaging, etc. A diagnosis of dementia or mild cognitive impairment may be given, but other cases will not receive any of these diagnoses. As a part of these investigations, a lumbar puncture is usually performed to analyze AD-markers in the cerebrospinal fluid (CSF). Approximately 200 lumbar punctures are performed annually, and an aliquot of each sample (1 - 2 mL) is routinely stored in a biobank for 5 years or longer. To the investigators knowledge, at least 300 samples are stored. A retrospective analysis of these CSF samples will form the basis for the investigators biochemical investigations. From these approximately 300 cases we will select 120 participants to include in our study. Those that received a diagnosis of dementia will be the case group, those that did not fulfil dementia criteria (around 25 %) will serve as a control group. Participants with the most complete available clinical data until we reach 120 inclusions will be included.

Data collection

Cognitive function and existing CSF data

The medical records from Minnesmottagningen include results from cognitive tests, e.g. MMSE, Clock Drawing Test, Trail Making Tests, etc. These will be retrieved and registered.

The diagnoses given at Minnesmottagningen, i.e. dementia (if available, also the etiological type of dementia), minor cognitive impairment, other or no diagnosis, will be documented.

The documented results of CSF-analyses of AD-markers, such as β-amyloid, tau and phospho-tau will be retrieved and registered.

Risk factors for Alzheimer disease and periodontitis

From the participants' medical records, information on known risk factors for AD and periodontitis will be collected, notably hypertension, hyperlipidemia, diabetes mellitus, smoking, alcohol consumption, overweight and obesity, coronary heart disease.

Periodontal evaluation

Dental records, including radiographs from the participants' dentists up to 15 years back will be searched for and reviewed. Periodontal status will be assessed by research dentists based on radiographs and clinical examinations extracted from the study participants' dental records.

CSF analyses

These analyses are viewed as explorative. Therefore, the investigators plan interim evaluations after the first 30 results (for each analysis), to estimate the feasibility of continued analysis. Some of the analyses will be performed at laboratories available to the research group, other analyses will be sent to established research laboratories. Analyses will include:

Bacterial DNA from selected species by Polymerase Chain Reaction (PCR). Gingipain analyses with Enzyme-Linked Immunosorbent Assay (ELISA) and with a specific sensor.

Antibodies against selected bacteria with ELISA. Cytokines, chemokines and growth factors with ELISA / Multiplex. The study is planned to include e.g Aggregatibacter actinomycetemcomitans, Tannerella forsythia and Treponema denticola, however, focusing on P. gingivalis.

Statistical considerations

The power analysis is based on a study from 2019. In CSF from 10 individuals with AD, P. gingivalis DNA was detected in seven, but no control CSFs were included. However, in their post-mortem brain parenchyma analyses, P. gingivalis toxins were present in 91-96 % of AD brains and 39-52 % of control brains. The investigators may envisage 70 % positive CSF findings in dementia participants versus 30 % in controls based on this. For 80 % statistical power and α set at 0.05, the investigators would need a minimum sample size of 61 patients. Due to the explorative nature of the investigators study and a number of uncertainties concerning these calculations, the investigators want to include 120 patients in the study, with an interim evaluation of the CSF analyses after 30 analyses.

Statistical analyzes will be carried out in the computer program Statistical Package for the Social Sciences (SPSS) and will include established standard analyzes, e.g. T-tests, Mann-Whitney tests, Pearson and Spearman correlations, logistic and multivariate regressions.

Significance and scientific novelty

The results from this study could provide support for the theory that periodontitis and specific bacteria, implicated in the development of periodontitis, are involved in the pathogenesis and development of dementia. Clarifying the disease mechanisms of Alzheimer's disease and other types of dementia is an important step toward finding more efficient strategies to prevent and treat these diseases in the future.

02

Conditions studied

  • Alzheimer Disease
  • Dementia
  • Periodontitis
03

In context

Periodontitis

1,637 studies on the registry are indexed under Periodontitis; 327 are open to participants now.

This study's planned enrollment of 120 is above the median of 90 across 430 observational studies indexed under Periodontitis.

Browse Periodontitis studies →

Lead sponsor

Region Örebro County is the lead sponsor of 123 studies on the registry; 30 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years to 110 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

A cohort of 120 patients that has been investigated for cognitive impairment at the Memory Clinic, Department of Geriatric Medicine, Örebro University Hospital and from which a sample of cerebrospinal fluid has been stored in biobank.

Inclusion criteria

  • Any person that has been investigated for possible cognitive impairment at Minnesmottagningen, Department of Geriatric Medicine, Örebro University Hospital, and has a CSF sample stored in the biobank. This includes patients who received a diagnosis of dementia (major cognitive disorder) and patients not so diagnosed.

Exclusion criteria

Exclusion Criteria:

  • No CSF sample available in biobank
  • Incomplete or unavailable clinical and radiological data in medical and dental records, concerning e.g. cognitive tests and AD-biomarker analyses
  • Dementia with known etiological diagnosis, e.g. dementia due to alcohol use disorder or traumatic brain injury.
  • Creutzfeldt-Jakob disease or other transmissible prion disease
  • Non-consenting persons
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
120 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Memory clinic cohort

    A cohort of 120 individuals that has been investigated for cognitive impairment at the Memory Clinic, Department of Geriatric Medicine, Örebro University Hospital and from which a sample of cerebrospinal fluid has been stored in biobank.

06

What researchers measure

Primary outcomes

  1. Bacteriological findings in relation to neurocognitive outcome

    The presence of DNA, antibodies and toxins from selected bacterial species in biobank stored cerebrospinal fluid.

    Time frame: 2022-10-01 - 2023-12-31

  2. Periodontitis in relation to neurocognitive outcome

    Retrospectively collected clinical and radiographic periodontal status

    Time frame: 2022-10-01 - 2023-12-31

07

Study locations

1 site
  • Region Örebro county
    Örebro, Orebro Lan 701 82, Sweden
08

References and documents

Publications

  • Dominy SS, Lynch C, Ermini F, Benedyk M, Marczyk A, Konradi A, Nguyen M, Haditsch U, Raha D, Griffin C, Holsinger LJ, Arastu-Kapur S, Kaba S, Lee A, Ryder MI, Potempa B, Mydel P, Hellvard A, Adamowicz K, Hasturk H, Walker GD, Reynolds EC, Faull RLM, Curtis MA, Dragunow M, Potempa J. Porphyromonas gingivalis in Alzheimer's disease brains: Evidence for disease causation and treatment with small-molecule inhibitors. Sci Adv. 2019 Jan 23;5(1):eaau3333. doi: 10.1126/sciadv.aau3333. eCollection 2019 Jan. PubMed 30746447 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 10, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05557617
Lead sponsor
Region Örebro County
Responsible party
Sponsor
First posted
Sep 28, 2022
Start date
Oct 30, 2020
Primary completion
Dec 31, 2024 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
Apr 10, 2024

Study contacts

Susanne Bejerot, Professor
study director · Region Örebro County

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion